2-氨基-5-甲氧基茚满
临床资料 | |
---|---|
商品名 | none |
其他名称 | 5-MeO-AI; 2,3-Dihydro-5-methoxy-1H-Inden-2-amine |
给药途径 | Oral |
法律规范状态 | |
法律规范 |
|
药物动力学数据 | |
生物利用度 | high |
药物代谢 | acetyl-aminoindandane |
生物半衰期 | non-linear |
排泄途径 | full |
识别信息 | |
| |
CAS号 | 73305-09-6 |
PubChem CID | |
ChemSpider | |
UNII | |
CompTox Dashboard (EPA) | |
化学信息 | |
化学式 | C10H13NO |
摩尔质量 | 163.22 g·mol−1 |
3D模型(JSmol) | |
| |
|
2-氨基-5-甲氧基茚满是一种有机化合物,化学式为C10H13NO。它是一种消遣性药物和预防酗酒的药物,最初于1998年在专利中以Markush结构被隐匿提及。[1]它可以5-甲氧基茚满-2-酮[2]或5-溴茚满-2-醇[3]为原料制得。它和盐酸反应,可以得到2-氨基-5-甲氧基茚满盐酸盐。[4]
参考文献
- ^ US 5708018,Haadsma-Svensson, Susanne R.; Bengt R. Andersson & Clas A. Sonesson et al.,“2-aminoindans as selective dopamine D3 ligands”,发表于1998-01-13,指定于Pharmacia & Upjohn Co.
- ^ Renhowe, Paul A.; Chu, Daniel; Boyce, Rustum; Ni, Zhi-jie; Duhl, David; Tozzo, Effie; Johnson, Kirk; Myles, David. Preparation of guanidinobenzamides as melanocortin-4 receptor agonists useful for treating diseases such obesity and type II diabetes. 2002 WO 2002018327 A2.
- ^ Yusuf Akbaba, Süleyman Göksu, Ertan Şahin, Hamdullah Kılıç, Hasan Seçen. Synthesis and asymmetric resolution of a dopaminergic compound: 2-amino-5-methoxyindane. Tetrahedron: Asymmetry. 2016-07, 27 (11-12): 475–479 [2022-08-03]. doi:10.1016/j.tetasy.2016.04.005. (原始内容存档于2022-02-16) (英语).
- ^ Chen, Xiaoli; Demarest, Keith T.; Lee, Jung; Matthews, Jay M.; Rybczynski, Philip. Preparation of substituted indanes and tetralins as PPARα modulators for treating Syndrome X. 2006 US 20060094786 A1.